-
Implications of Hydrocephalus on FDG-PET Statistical Parametric Mapping Analysis in Neurodegenerative Disease Evaluation
Am J Neuroradiol, Aug 2025
-
Medicare Coverage of Amyloid PET: Implications for Clinical Practice
Am J Neuroradiol, Oct 2023
-
Clinical Utility of [F18]-Fluciclovine PET/MRI for Differentiating True Progression from Treatment-Related Changes in Patients with Glioblastoma
AJNR Am J Neuroradiol, Dec 2025
-
Embedding Sustainability into the Imaging and Care of Patients with Cancer
Radiol Imaging Cancer, Nov 2025
-
Organ and tumour dosimetry of 177Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a Phase I trial
Eur J Nucl Med Mol Imaging, May 2025
-
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
Thyroid, Aug 2025
-
Revolutionizing prostate cancer treatment: PSMA-targeted therapy in modern therapeutics
Rev Esp Med Nucl Imagen Mol (Engl Ed), May 2025
-
Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis
Prostate, Jan 2025
-
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution
Eur Urol Oncol, Jun 2025
-
18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases
Eur J Radiol, Dec 2024
-
Alternate CMS Payment Structure for Outpatient Services: A Road to Improving Access to Molecular Imaging in Oncologic Care
RSNA: Imaging Cancer, Nov 2023
